Amarasuriya Umesh Kalum, Myles Puja R, Sanders Robert David
Stockton-on-Tees Adult Learning Disability Service, Tees Esk & Wear Valleys NHS Foundation Trust, UK.
Curr Drug Saf. 2012 Nov 1;7(5):367-71.
Benzodiazepines are World Health Organisation essential medicines used in the treatment of alcohol withdrawal, anaesthesia, sedation, anxiolysis, behavioural disturbance, epilepsy, insomnia, palliative care, and muscle spasm. Despite their widespread use concerns remain over their long-term safety through both neuronal and non-neuronal effects. We conducted a systematic review to identify vulnerable populations of patients who may be at increased risk of harm from benzodiazepines. We identified three potentially "at risk" groups of patients, those with renal disease, lung disease and those recently hospitalised. However methodological limitations including selection bias, vague descriptors of benzodiazepine use and inappropriate grouping together of benzodiazepines with other medications, precluded definitive conclusions. Future studies should concentrate on these groups to identify the long-term safety of benzodiazepines in these patient groups.
苯二氮䓬类药物是世界卫生组织的基本药物，用于治疗酒精戒断、麻醉、镇静、抗焦虑、行为障碍、癫痫、失眠、姑息治疗和肌肉痉挛。尽管它们被广泛使用，但由于其对神经元和非神经元的影响，人们对其长期安全性仍存在担忧。我们进行了一项系统综述，以确定可能因苯二氮䓬类药物而面临更高伤害风险的脆弱患者群体。我们确定了三类潜在的“风险”患者群体，即患有肾脏疾病、肺部疾病的患者以及近期住院的患者。然而，方法学上的局限性，包括选择偏倚、苯二氮䓬类药物使用的模糊描述以及将苯二氮䓬类药物与其他药物不恰当地归为一组，妨碍了得出明确结论。未来的研究应关注这些群体，以确定苯二氮䓬类药物在这些患者群体中的长期安全性。
